Fleroxacin Capsules

This product is a quinolone antibacterial drug, which has strong antibacterial effect on Gram-negative bacteria, including Escherichia coli, Klebsiella pneumoniae, Proteus, Salmonella typhi, Salmonella paratyphi, Shigella, Enterobacter cloacae, Enterobacter aerogenes, Citrobacter, Serratia marcescens, Pseudomonas aeruginosa, Neisseria meningitidis, Haemophilus influenzae, Moracata, Legionella pneumophila, Neisseria gonorrhoeae, etc. It also has moderate antibacterial effect on Gram-positive cocci such as Staphylococcus and hemolytic Streptococcus. The mechanism of action of this product is to inhibit the bacterial DNA gyrase and thus kill bacteria.

The main ingredient of this product is fleroxacin.

This product is a hard capsule, and the contents are white or off-white granules or powder.

It can be used for respiratory system infections such as acute bronchitis, acute exacerbation of chronic bronchitis and pneumonia caused by bacteria sensitive to this product; urogenital system infections such as cystitis, pyelonephritis, prostatitis, epididymitis, gonorrhea Neisseria urethritis; digestive system infections such as typhoid Salmonella infection and bacterial dysentery; skin and soft tissue infections, bone infections, abdominal infections and pelvic infections, etc.

Oral administration, 0.2-0.4 g per day, divided into 1-2 doses. The general course of treatment is 7-14 days.

1. Gastrointestinal reactions are relatively common and may manifest as abdominal discomfort or pain, diarrhea, nausea and vomiting, loss of appetite, etc. 2. Central nervous system reactions may include dizziness, headache, excitement, drowsiness or insomnia. 3. Allergic reactions include rash, skin itching, and occasionally exudative erythema multiforme and angioneurotic edema. A small number of patients have photosensitivity reactions. 4. A small number of patients may have increased blood aminotransferase and blood urea nitrogen and decreased peripheral blood white blood cells, which are mostly mild and transient. 5. Occasionally may occur: 1. Epileptic seizures, mental abnormalities, irritability, confusion, hallucinations, tremors; 2. Interstitial nephritis manifestations such as hematuria, fever, rash; 3. Crystalluria, more common when used in high doses; 4. Joint pain.

1. Those who are allergic to this product or quinolone drugs are prohibited from using this product. 2. Pregnant women, lactating women and patients under 18 years old are prohibited from using this product.

Precautions for children: Patients under 18 years old are prohibited from using this product. Precautions for pregnancy and lactation: Pregnant and lactating women are prohibited from using this product. Precautions for the elderly: Elderly patients have decreased renal function and the dosage should be reduced as appropriate.

1. The aluminum and magnesium contained in didanosine (DDI) preparations can chelate with fluoroquinolones and should not be used together. 2. Urine alkalinizers can reduce the solubility of this product in urine, leading to crystalluria and nephrotoxicity. 3. Probenecid can delay the excretion of this product, increase the blood concentration of this product and produce toxicity. 4. Antacids containing aluminum or magnesium can reduce the oral absorption of this product. It is recommended to avoid taking it together. If it cannot be avoided, it is recommended to take it 2 hours before or 6 hours after taking this product.

Keep in a light-proof and airtight container.

0.1g

24 months

Suzhou Yushi Pharmaceutical Co., Ltd.

• Founded in:

  2003-04-02

• Address:

  No. 188, Nanhu Avenue, Nanhu Industrial Zone, Xinzhuang, Changshu City

• Tax NO.:

  913205817473463096

• Registered Funds:

  38 million yuan

• Website:

  Log in to view

• Email:

  Log in to view